Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
1 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
0 |
Cash Flow (TTM) (Millions $) |
0 |
Capital Exp. (TTM) (Millions $) |
0 |
American Biogenetic Sciences Inc.
American Biogenetic Sciences Inc. (AMBS) is a biopharmaceutical company headquartered in Massachusetts, United States. It focuses on the development and commercialization of novel diagnostics and therapeutics for diseases such as cancer, HIV/AIDS, and neurological disorders.
With a mission to improve human health, AMBS utilizes its expertise in immunology, molecular biology, and genetics to develop innovative products. The company has a diverse portfolio of patented technologies and intellectual properties, which it leverages to create products that address medical unmet needs.
AMBS has established partnerships with various research institutions and academic centers to collaborate on the development of new drugs and diagnostics. It has also entered into licensing agreements with pharmaceutical companies to further expand its product pipeline.
One of the key areas of focus for AMBS is the development of potential treatments for Alzheimer's disease. The company has conducted extensive research in this field and aims to develop therapeutics that can prevent the progression of the disease and improve patient outcomes.
In addition to its drug development efforts, AMBS offers laboratory services, including sample testing and patient analysis. The company prides itself on its commitment to quality, integrity, and transparency in all aspects of its operations.
Overall, American Biogenetic Sciences Inc. is an innovative biopharmaceutical company dedicated to advancing healthcare through the development of novel diagnostics and therapeutics for various diseases.
|